未登录

T

Toshimitsu Yamaoka

Showa University

H指数:23

被引数:1,800

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer

HER2抑制剂在非小细胞肺癌中的开发与临床应用的最新进展

Biomolecules 2025, Vol. 15, Page 1443

IF0

2025-10-120

OAAI

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation

IF5.2

2022-07-146

OAAI

Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

IF2.7

2021-02-0120

OAAI

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer Comment

TRANSLATIONAL LUNG CANCER RESEARCH

IF3.5

2020-10-013

OAAI

KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR

CANCER RESEARCH

IF16.6

2019-07-011

PRE

KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-01-0244

OAAI

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

在携带EGFR突变的肺腺癌中鉴定出不同的阿法替尼耐药机制

MOLECULAR CANCER RESEARCH

IF4.7

2017-07-0441

OAAI

Tyrosine kinase inhibitor resistance were decreased in spheroid culture platform

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

MOLECULAR CANCER THERAPEUTICS

IF5.5

2016-12-0128

OAAI

The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines

CANCER RESEARCH

IF16.6

2016-07-151

PRE

Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells

CANCER RESEARCH

IF16.6

2016-07-150

PRE

TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Contribution of miR-205 in gefitinib-resistant lung cancer cell lines

CANCER RESEARCH

IF16.6

2014-10-010

PRE

CLINICAL BENEFIT OF 2ND EGFR-TKI RETREATMENT ON OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

ANNALS OF ONCOLOGY

IF65.4

2013-11-011

OAAI

The characteristics of an acquired dual resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR.

CANCER RESEARCH

IF16.6

2013-04-010

PRE

Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution

CANCER RESEARCH

IF16.6

2012-04-010

PRE

HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

IF3.3

2011-08-0137

OAAI

Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2011-06-019

PREAI